Big pharma to add $60bn in sales by 2024
This article was originally published in Scrip
Big pharma companies are set to grow their revenues by a modest 1.3% a year over the next 10 years, and oncology will slip from the top spot as the most lucrative therapy area. So says a new report on the outlook for big pharma from Datamonitor Healthcare. It forecasts that the top 16 US/European big pharma companies will see prescription drug revenues grow by $60bn to reach $499bn in 2024.